Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
| Autor: | Zeidan, Amer M *, Ando, Kiyoshi, Rauzy, Odile, Turgut, Mehmet, Wang, Ming-Chung, Cairoli, Roberto, Hou, Hsin-An, Kwong, Yok-Lam, Arnan, Montserrat, Meers, Stef, Pullarkat, Vinod, Santini, Valeria, Malek, Kamel, Kiertsman, Flavia, Niolat, Julie, Ramos, Pedro Marques, Menssen, Hans D, Fenaux, Pierre, Miyazaki, Yasushi, Platzbecker, Uwe |
|---|---|
| Zdroj: | In The Lancet Haematology January 2024 11(1):e38-e50 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|